Table 1.
Cohort demographics
| Cohort | Group | n (F/M) | Age | MMSE | Aβ1-42/1-40 | P-tau181 | T-tau |
|---|---|---|---|---|---|---|---|
| TRIAD CSF | Young | 5 (3/2) | 23 (1, 22–24)a,b,c,d | 30 (0, 30–30) | 0.095 (0.010, 0.088–0.10)b,d | 24 (7, 23–31)b | 191 (36, 161–222)b |
| CU− | 15 (11/4) | 71 (5, 68–74)a | 29 (1, 28–30) | 0.093 (0.010, 0.082–0.098)b,d | 33 (10, 29–42)b | 252 (72, 199–335)b | |
| CU+6 | 10 (5/5) | 73 (3, 70–76)a | 29 (1, 29–30) | 0.059 (0.011, 0.046–0.067)a,b | 52 (22, 41–72)b | 395 (126, 292–488)b | |
| CI− | 12 (6/6) | 65 (8, 60–68) | 29 (3, 26–30) | 0.095 (0.014, 0.091–0.099)b | 33 (13, 19–36)b | 250 (88, 159–294)b | |
| CI+8 | 28 (11/17) | 68 (9, 60–77) | 25 (4, 21–29) | 0.042 (0.009, 0.037–0.051) | 82 (50, 64–118) | 551 (323, 398–778) |
Notes: Detailed diagnosis for the CI+ group consisted of the following: 15 AD and 13 MCI, while the CI− group consisted of 3 MCI, 4 FTD, and 5 patients with uncertain diagnosis. Analysis of variance (ANOVA) followed by Tukey’s post hoc test was used for the continuous variables. The level of significance used was p ≤ 0.05. Data presented as median (standard deviation, interquartile interval) and in ng/L. aSignificant ANOVA post hoc Tukey test compared to CI−. bSignificant ANOVA post hoc Tukey test compared to CI+. cSignificant ANOVA post hoc Tukey test compared to CU−. dSignificant ANOVA post hoc Tukey test compared to CU+
Abbreviations: MMSE Mini-Mental State Exam Score, Aβ1-42/1-40 amyloid beta protein ratio 1-42/1-40, P-tau181 total tau, T-tau phosphorylated tau at amino acid Thr181, CU− cognitively unimpaired Aβ negative, CU+ cognitively unimpaired Aβ positive, CI− cognitively impaired Aβ negative, CI+ cognitively impaired Aβ positive